NICE has recommended regular NHS funding for Opdivo in advanced melanoma, including in combination with BMS' other immunotherapy, Yervoy. It has also backed Keytruda in advanced skin cancer.
Zacks Investment Research on MSN6d
EC Approves Bristol Myers' Opdivo Plus Yervoy for First-Line HCCBristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...
2d
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.
Deborah S. Sarnoff, M.D., talks about the recent breakthrough treatments that are paving the way to treat patients with ...
A Bristol Myers Squibb immunotherapy currently approved as a first-line treatment for metastatic melanoma has failed a pivotal clinical trial intended to support expanding the therapy’s use to ...
Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical ...
Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic ...
The combination of Opdivo and Yervoy is also approved for metastatic melanoma, first-line treatment of adult patients with metastatic non-small cell lung cancer, first-line treatment of adult ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback